Area of research
Pulmonary and Respiratory Medicine · Radiation
Research interest
Research interests include Lung Cancer Diagnosis and Treatment, Advanced Radiotherapy Techniques, Lung Cancer Treatments and Mutations, and Brain Metastases and Treatment.
Stereotactic Arrhythmia Radiation Therapy Versus Repeat Catheter Ablation for Refractory Ventricular Tachycardia: 3-Year Safety and Efficacy Outcomes.
Early ctDNA stratifies survival in locally advanced and oligometastatic lung cancer treated with radiotherapy.
Radiation Oncology-Biology Integration Network (ROBIN): Bridging the gap between biological research and clinical practice.
Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer.
Direct-to-Unit Stereotactic Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy for Spine Metastasis
Figure S4 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Figure S5 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Data from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Figure S1 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Table S1 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Table S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Cardiac substructure radiotherapy dose and changes in physical activity and quality of life after chemoradiotherapy for NSCLC: a secondary analysis of the CLARITY prospective study
Figure S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Extended Material and Methods from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Table S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Figure S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Stereotactic arrhythmia radioablation (STAR)-A systematic review and meta-analysis of prospective trials on behalf of the STOPSTORM.eu consortium.
Cardiotoxicity following thoracic radiotherapy for lung cancer.
Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.
STAR Locally Prolongs Effective Refractory Period and Increases Ventricular Tachycardia Cycle Length Without Short-Term Scar Formation or Functional Decline: Insights From a Translational Porcine Model Study.
Safety and Efficacy of Stereotactic Cardiac Radio-Ablation for Ventricular Tachycardia in Patients at High Risk of Mortality.
Using Integrin α<sub>v</sub>β<sub>6</sub>-Targeted Positron Emission Tomography Imaging to Longitudinally Monitor Radiation-Induced Pulmonary Fibrosis In Vivo.
How to Avoid Collapsing Under the Pressure of Managing Atelectasis During Lung Cancer Radiation Therapy.
Erratum to: Gondi V, Deshmukh S, Brown PD, et al. Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001. Int J Radiat Oncol Biol Phys. 2023;117:571-580.
Resistance is Futile: Stereotactic Body Radiation Therapy for Oligoprogressive Non-small Cell Lung Cancer.
Correction: Cardiotoxicity following thoracic radiotherapy for lung cancer.
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment <sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non–Small Cell Lung Cancer
Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer
Management of Stage III Non-Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer.